CN1202828C - 二膦酸在制备抑制或逆转血管发生的药物中的用途 - Google Patents

二膦酸在制备抑制或逆转血管发生的药物中的用途 Download PDF

Info

Publication number
CN1202828C
CN1202828C CNB008092117A CN00809211A CN1202828C CN 1202828 C CN1202828 C CN 1202828C CN B008092117 A CNB008092117 A CN B008092117A CN 00809211 A CN00809211 A CN 00809211A CN 1202828 C CN1202828 C CN 1202828C
Authority
CN
China
Prior art keywords
treatment
acid
diphosphonic acid
patient
purposes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB008092117A
Other languages
English (en)
Chinese (zh)
Other versions
CN1384749A (zh
Inventor
T·奥库诺
J·格林
J·M·伍德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315578&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1202828(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9911926.5A external-priority patent/GB9911926D0/en
Priority claimed from GBGB9925131.6A external-priority patent/GB9925131D0/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1384749A publication Critical patent/CN1384749A/zh
Application granted granted Critical
Publication of CN1202828C publication Critical patent/CN1202828C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB008092117A 1999-05-21 2000-05-19 二膦酸在制备抑制或逆转血管发生的药物中的用途 Expired - Fee Related CN1202828C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9911926.5 1999-05-21
GBGB9911926.5A GB9911926D0 (en) 1999-05-21 1999-05-21 Organic compounds
GB9925131.6 1999-10-22
GBGB9925131.6A GB9925131D0 (en) 1999-10-22 1999-10-22 Organic compounds

Publications (2)

Publication Number Publication Date
CN1384749A CN1384749A (zh) 2002-12-11
CN1202828C true CN1202828C (zh) 2005-05-25

Family

ID=26315578

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB008092117A Expired - Fee Related CN1202828C (zh) 1999-05-21 2000-05-19 二膦酸在制备抑制或逆转血管发生的药物中的用途

Country Status (21)

Country Link
US (2) US20020142996A1 (https=)
EP (1) EP1178810B8 (https=)
JP (1) JP2003500352A (https=)
KR (1) KR100763064B1 (https=)
CN (1) CN1202828C (https=)
AT (1) ATE293450T1 (https=)
AU (1) AU775079B2 (https=)
BR (1) BR0010808A (https=)
CA (1) CA2374049A1 (https=)
DE (1) DE60019580T2 (https=)
DK (1) DK1178810T3 (https=)
ES (1) ES2240106T3 (https=)
HU (1) HUP0201329A3 (https=)
IL (2) IL146520A0 (https=)
NO (1) NO322212B1 (https=)
NZ (1) NZ515541A (https=)
PL (1) PL351674A1 (https=)
PT (1) PT1178810E (https=)
SK (1) SK16682001A3 (https=)
TW (1) TWI224504B (https=)
WO (1) WO2000071104A2 (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1591122B1 (en) * 2000-06-20 2012-09-26 Novartis AG Method of administering bisphosphonates
CA2410201C (en) 2000-06-20 2010-10-26 Novartis Ag Zoledronic acid or salts thereof for use in the treatment of conditions of abnormally increased bone turnover
EP1365769B1 (en) * 2001-02-06 2011-01-26 The Sydney Children's Hospitals Network (Randwick and Westmead) (incorporating The Royal Alexandra Hospital for Children) A drug for the treatment of osteonecrosis and for the management of patients at risk of developing osteonecrosis
EP1418897A2 (en) * 2001-05-02 2004-05-19 Novartis AG Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
ES2336312T3 (es) * 2001-07-16 2010-04-12 Universite Paris 13 Procedimiento de preparacion de derivados de bisfosfonatos.
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
CA2478317A1 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. Methods of preventing or treating disorders by administering an integrin .alpha.v.beta.3 antagonist in combination with an hmg-coa reductase inhibitor or a bisphosphonate
RU2387451C2 (ru) 2002-05-10 2010-04-27 Ф.Хоффманн-Ля Рош Аг Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза
EP1426052B1 (en) * 2002-12-02 2009-09-02 Innate Pharma Compositions comprising interleukin-2 and gamma-delta T cell activator and uses thereof
CA2532948A1 (en) * 2003-07-21 2005-02-17 Novartis Ag Combinations of a cathepsin k inhibitor and a bisphophonate in the treatment of bone metastasis, tumor growth and tumor-induced bone loss
SK50782006A3 (sk) † 2004-02-26 2007-03-01 Zentiva, A. S. Amorfné formy risedronátu monosodného
EP1930011B1 (en) * 2004-08-23 2011-08-17 Teva Pharmaceutical Industries Ltd Crystalline form of ibandronate sodium
US7914810B2 (en) * 2005-05-06 2011-03-29 Synthes Usa, Llc Methods for the in situ treatment of bone cancer
PE20070360A1 (es) * 2005-09-01 2007-04-19 Novartis Ag Composiciones de liposomas
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
EP2255199A1 (en) * 2008-02-19 2010-12-01 Jovesis Inc. Microparticle compositions to modify cancer promoting cells
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
CA2769633C (en) * 2009-07-31 2017-06-06 Thar Pharma, Llc Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2015018659A1 (en) * 2013-08-05 2015-02-12 Vib Vzw Glutamine synthetase inhibitors for inhibition of pathological angiogenesis
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) * 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
DE3425812A1 (de) * 1984-07-13 1986-01-16 Deutsches Krebsforschungszentrum, 6900 Heidelberg Neue 1-hydroxy-1,1-diphosphonsaeureverbindungen, verfahren zu ihrer herstellung und pharmakologische zubereitungen, insbesondere zur behandlung von knochentumoren
IT1187828B (it) * 1985-05-24 1987-12-23 Gentili Ist Spa Composizione farmaceutica a base di difosfonati per il trattamento dell aretrosi
DE3623397A1 (de) * 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
US5116864A (en) * 1991-04-09 1992-05-26 Indiana University Foundation Method for preventing restenosis following reconfiguration of body vessels
US5358941A (en) * 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
SE9402001D0 (sv) * 1994-06-09 1994-06-09 Leiras Oy Pyridylbisphosphonates for use as a therapeutical agent
IT1290444B1 (it) * 1997-03-27 1998-12-03 Boehringer Mannheim Italia Coniugati di bis-fosfonati con funzionalita' alchilanti aventi attivita' antitumorale
TR200000145T2 (tr) * 1997-07-22 2000-05-22 Merck & Co. Inc. Kemik erimesini durdurmak için bir yöntem
US5994329A (en) * 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6048861A (en) * 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
EP0998934A4 (en) * 1997-12-25 2005-09-14 Toray Industries REMEDIES AGAINST INTRAMEDULLARY DISEASES
US6416964B2 (en) * 1998-01-29 2002-07-09 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
AU760703B2 (en) * 1998-01-29 2003-05-22 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
US6426367B1 (en) * 1999-09-09 2002-07-30 Efa Sciences Llc Methods for selectively occluding blood supplies to neoplasias
US6677320B2 (en) * 2000-01-20 2004-01-13 Hoffmann-La Roches Inc. Parenteral bisphosphonate composition with improved local tolerance

Also Published As

Publication number Publication date
EP1178810B1 (en) 2005-04-20
DE60019580D1 (de) 2005-05-25
EP1178810A2 (en) 2002-02-13
US20040176327A1 (en) 2004-09-09
DE60019580T2 (de) 2006-03-09
EP1178810B8 (en) 2005-07-27
PL351674A1 (en) 2003-05-19
NO20015638L (no) 2002-01-15
KR20010113830A (ko) 2001-12-28
HUP0201329A3 (en) 2005-02-28
AU5214100A (en) 2000-12-12
US20020142996A1 (en) 2002-10-03
CA2374049A1 (en) 2000-11-30
SK16682001A3 (sk) 2002-04-04
NZ515541A (en) 2003-03-28
AU775079B2 (en) 2004-07-15
DK1178810T3 (da) 2005-07-11
NO322212B1 (no) 2006-08-28
TWI224504B (en) 2004-12-01
IL146520A (en) 2006-09-05
WO2000071104A2 (en) 2000-11-30
ES2240106T3 (es) 2005-10-16
HUP0201329A2 (en) 2002-08-28
JP2003500352A (ja) 2003-01-07
ATE293450T1 (de) 2005-05-15
IL146520A0 (en) 2002-07-25
WO2000071104A3 (en) 2001-07-19
PT1178810E (pt) 2005-08-31
KR100763064B1 (ko) 2007-10-04
CN1384749A (zh) 2002-12-11
BR0010808A (pt) 2002-08-27
NO20015638D0 (no) 2001-11-19

Similar Documents

Publication Publication Date Title
CN1202828C (zh) 二膦酸在制备抑制或逆转血管发生的药物中的用途
CN1277545C (zh) 二膦酸类化合物在制备用于治疗与前列腺癌有关的骨转移瘤的药物中的用途
CN1272013C (zh) 二膦酸盐在制备用于治疗骨更新异常增加的病症的药物中的应用
CN1535152A (zh) 二膦酸类化合物在治疗疼痛方面的应用
KR20150035597A (ko) 염증성 통증 및 관련 병태의 경감을 위한, 졸레드론산 또는 관련 화합물을 포함하는 조성물
US20090209493A1 (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor
CN1681516A (zh) 预防或减少髋部骨折后继发性骨折的方法
US6255288B1 (en) Certain methanebisphosphonic acid derivatives in fracture healing
TW200301704A (en) Method for the treatment of bone disorders
HK1080711B (en) Use of bisphosphonates for the munufacture of a medicament for the treatment of bone metastasis associated with prostate cancer
US8623845B1 (en) Pharmaceutical composition for preventing or treating Diabetes mellitus comprising bisphophonates
HK1072539B (en) Use of bisphosphonates in the preparation of a medicment for the treatment of conditings of abnormally increased bone turnover
RU2261100C2 (ru) Применение бисфосфоновых кислот для лечения ангиогенеза
JP4692283B2 (ja) 悪性黒色腫治療剤
HK1068550A (en) Use of bisphosphonates for pain treatment
HK1080734B (en) Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor

Legal Events

Date Code Title Description
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20050525